tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ATXI Stock Latest News

Avenue Therapeutics Announces Reverse Stock Split
Press ReleasesAvenue Therapeutics Announces Reverse Stock Split
17h ago
ATXI
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
PremiumPress Releases
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
1M ago
ATXI
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
PremiumCompany Announcements
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
1M ago
ATXI
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
PremiumPress Releases
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
1M ago
ATXI
Avenue Therapeutics granted extension for Nasdaq compliance
PremiumThe Fly
Avenue Therapeutics granted extension for Nasdaq compliance
1M ago
ATXI
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
PremiumPress ReleasesAvenue Therapeutics Receives Positive Listing Determination from Nasdaq
1M ago
ATXI
Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting
PremiumThe Fly
Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting
1M ago
ATXI
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
PremiumPress Releases
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
1M ago
ATXI
ATXI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ATXI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
ATXI
Avenue Therapeutics Shareholders Approve Stock Capacity Hike
PremiumCompany Announcements
Avenue Therapeutics Shareholders Approve Stock Capacity Hike
2M ago
8K
ATXI
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
PremiumPress Releases
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
2M ago
ATXI
Avenue Therapeutics announces publication of preclinical data of BAER-101
PremiumThe Fly
Avenue Therapeutics announces publication of preclinical data of BAER-101
2M ago
ATXI
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
PremiumPress ReleasesAvenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
2M ago
ATXI
Avenue Therapeutics files to sell 33.08M shares of common stock for holders
PremiumThe Fly
Avenue Therapeutics files to sell 33.08M shares of common stock for holders
3M ago
ATXI
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
PremiumPress Releases
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
3M ago
ATXI
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
PremiumPress Releases
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
4M ago
ATXI
Avenue Therapeutics enters warrant exercise transactions for $5M in procceeds
PremiumThe Fly
Avenue Therapeutics enters warrant exercise transactions for $5M in procceeds
4M ago
ATXI
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
PremiumPress Releases
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
4M ago
ATXI
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
PremiumThe Fly
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
4M ago
ATXI
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
PremiumPress ReleasesAvenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy’s Disease)
4M ago
ATXI
Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201
PremiumThe Fly
Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201
4M ago
ATXI
Avenue Therapeutics initiated yesterday with a Buy at Maxim
PremiumThe Fly
Avenue Therapeutics initiated yesterday with a Buy at Maxim
4M ago
ATXI

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >